Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Vishal Kumar, Ashutosh Bahuguna & Myunghee Kim. (2023) Molecular insights into binding of bioactive compounds from essential oil of Trachyspermum ammi with human programmed cell death protein 1. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-11.
Read now
Read now
Linlin Guo, Jay Overholser, Heather Darby, Nicholas J. Ede & Pravin T.P Kaumaya. (2022) A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). OncoImmunology 11:1.
Read now
Read now
Jorge Cebada, Martin Perez-Santos, Cindy Bandala, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Pérez Peña, Eduardo Monjaraz, Amira Flores & Maricruz Anaya-Ruiz. (2021) OX40 agonists for cancer treatment: a patent review. Expert Opinion on Therapeutic Patents 31:1, pages 81-90.
Read now
Read now
Qiaohong Geng, Sagar O. Rohondia, Harras J. Khan, Peifu Jiao & Q. Ping Dou. (2020) Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opinion on Therapeutic Patents 30:9, pages 677-694.
Read now
Read now
Martin Perez-Santos, Maricruz Anaya-Ruiz, Jorge Cebada, Cindy Bandala, Gerardo Landeta, Patricia Martínez-Morales & Nemesio Villa-Ruano. (2019) LAG-3 antagonists by cancer treatment: a patent review. Expert Opinion on Therapeutic Patents 29:8, pages 643-651.
Read now
Read now
Shabnam Shaabani, Harmen P.S. Huizinga, Roberto Butera, Ariana Kouchi, Katarzyna Guzik, Katarzyna Magiera-Mularz, Tad A. Holak & Alexander Dömling. (2018) A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018). Expert Opinion on Therapeutic Patents 28:9, pages 665-678.
Read now
Read now
Mauro Alaibac. (2018) Small molecule inhibitors for cutaneous T-cell lymphomas. Expert Opinion on Orphan Drugs 6:5, pages 345-350.
Read now
Read now
Xiangjun Kong, Qianru Zhang, Yunfeng Lai, Hao Hu, Xin Chen & Yuanjia Hu. (2018) Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opinion on Therapeutic Patents 28:1, pages 69-80.
Read now
Read now
Articles from other publishers (66)
Lulu Zhang, Siqi Zhang, Jiang Wu, Yanrong Wang, Yuxuan Wu, Xiaona Sun, Xingkai Wang, Jieting Shen, Lin Xie, Yiding Zhang, Hailong Zhang, Kuan Hu, Feng Wang, Rui Wang & Ming-Rong Zhang. (2023) Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Molecular Pharmaceutics 20:8, pages 4256-4267.
Crossref
Crossref
Qiuzi Dai, Qinsheng Sun, Xiaorong Ouyang, Jinyang Liu, Liye Jin, Ahao Liu, Binsheng He, Tingting Fan & Yuyang Jiang. (2023) Antitumor Activity of s-Triazine Derivatives: A Systematic Review. Molecules 28:11, pages 4278.
Crossref
Crossref
Elisa Bianconi, Alessandra Riccio, Luana Ruta, Carlo Bigiotti, Andrea Carotti, Sonia Moretti, Bruno Cerra, Antimo Gioiello, Simone Ferlin, Efisio Puxeddu & Antonio Macchiarulo. (2023) Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency. International Journal of Molecular Sciences 24:6, pages 5535.
Crossref
Crossref
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska-Kołat, Mateusz Gawrysiak, Rafał Drozda, Ismail Celik & Renata Kontek. (2023) PD-1/PD-L1 and DNA Damage Response in Cancer. Cells 12:4, pages 530.
Crossref
Crossref
Marawan Ahmed, Aravindhan Ganesan & Khaled Barakat. (2022) Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1. BMC Chemistry 16:1.
Crossref
Crossref
Pujan Sasmal, Sajeev Kumar Babasahib, B.R. Prashantha Kumar & Nulgumnalli Manjunathaiah Raghavendra. (2022) Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. Bioorganic & Medicinal Chemistry 73, pages 117001.
Crossref
Crossref
Alexander Batista-Duharte, Fakhri Hassouneh, Pablo Alvarez-Heredia, Alejandra Pera & Rafael Solana. (2022) Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches. Pharmaceutics 14:8, pages 1721.
Crossref
Crossref
Wen-Hao Wu, Jianwen Guo, Longshuai Zhang, Wen-Bin Zhang & Weiping Gao. (2022) Peptide/protein-based macrocycles: from biological synthesis to biomedical applications. RSC Chemical Biology 3:7, pages 815-829.
Crossref
Crossref
Fabian Krutzek, Klaus Kopka & Sven Stadlbauer. (2022) Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals 15:6, pages 747.
Crossref
Crossref
Raphaël Le Biannic, Romain Magnez, Frédérique Klupsch, Natascha Leleu-Chavain, Bryan Thiroux, Morgane Tardy, Hassiba El Bouazzati, Xavier Dezitter, Nicolas Renault, Gérard Vergoten, Christian Bailly, Bruno Quesnel, Xavier Thuru & Régis Millet. (2022) Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction. European Journal of Medicinal Chemistry 236, pages 114343.
Crossref
Crossref
André E. Nel, Kuo-Ching Mei, Yu-Pei Liao & Xiangsheng Liu. (2022) Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs. ACS Nano 16:4, pages 5184-5232.
Crossref
Crossref
Ya‐Nan Tan, Jian‐Dong Huang, Yong‐Peng Li, Shan‐Shan Li, Min Luo, Jie Luo, Anne Wing‐Mui Lee, Li Fu, Fu‐Qiang Hu & Xin‐Yuan Guan. (2021) Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy against Metastatic Tumors. Advanced Healthcare Materials 11:6, pages 2101496.
Crossref
Crossref
Chih-Hao Lu, Wei-Min Chung, Chun-Hao Tsai, Ju-Chien Cheng, Kai-Cheng Hsu & Huey-En Tzeng. (2022) In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction. Scientific Reports 12:1.
Crossref
Crossref
Pasquale Russomanno, Giulia Assoni, Jussara Amato, Vincenzo Maria D’Amore, Riccardo Scaglia, Diego Brancaccio, Martina Pedrini, Giovanna Polcaro, Valeria La Pietra, Paolo Orlando, Marianna Falzoni, Linda Cerofolini, Stefano Giuntini, Marco Fragai, Bruno Pagano, Greta Donati, Ettore Novellino, Cristina Quintavalle, Gerolama Condorelli, Francesco Sabbatino, Pierfausto Seneci, Daniela Arosio, Stefano Pepe & Luciana Marinelli. (2021) Interfering with the Tumor–Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors. Journal of Medicinal Chemistry 64:21, pages 16020-16045.
Crossref
Crossref
Xin Li, Yu Zhen & Shanshan Li. (2021) Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. Materials & Design 209, pages 109958.
Crossref
Crossref
Lovika Mittal, Rajiv K. Tonk, Amit Awasthi & Shailendra Asthana. (2021) Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. Archives of Biochemistry and Biophysics 713, pages 109059.
Crossref
Crossref
Kun Tu, Yulin Yu, Yi Wang, Ting Yang, Qian Hu, Xianya Qin, Jingyao Tu, Conglian Yang, Li Kong & Zhiping Zhang. (2021) Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade. ACS Applied Materials & Interfaces 13:33, pages 39003-39017.
Crossref
Crossref
Wei Wang, S. Cyrus Khojasteh & Dian Su. (2021) Biosynthetic Strategies for Macrocyclic Peptides. Molecules 26:11, pages 3338.
Crossref
Crossref
Yubo Wang, Yuanyuan Zhou, Sheng Cao, Yue Sun, Zhiqiang Dong, Chen Li, Haoran Wang, Yuhong Yao, Haiyan Yu, Xiangyi Song, Ming Li, Jiefu Wang, Mingming Wei, Guang Yang & Cheng Yang. (2021) In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorganic Chemistry 111, pages 104833.
Crossref
Crossref
Roberto Butera, Marta Ważyńska, Katarzyna Magiera-Mularz, Jacek Plewka, Bogdan Musielak, Ewa Surmiak, Dominik Sala, Radoslaw Kitel, Marco de Bruyn, Hans W. Nijman, Philip H. Elsinga, Tad A. Holak & Alexander Dömling. (2021) Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS Medicinal Chemistry Letters 12:5, pages 768-773.
Crossref
Crossref
Wenjie Zhai, Xiuman Zhou, Mingxia Zhai, Wanqiong Li, Yunhui Ran, Yixuan Sun, Jiangfeng Du, Wenshan Zhao, Lingxiao Xing, Yuanming Qi & Yanfeng Gao. (2020) Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Science China Life Sciences 64:4, pages 548-562.
Crossref
Crossref
Viktor A. Urban, Alexander I. Davidovskii & Valery G. Veresov. (2021) In silico analysis of resveratrol induced PD-L1 dimerisation. Journal of the Belarusian State University. Biology:1, pages 39-47.
Crossref
Crossref
Lovika Mittal, Mitul Srivastava, Anita Kumari, Rajiv K. Tonk, Amit Awasthi & Shailendra Asthana. (2021) Interplay among Structural Stability, Plasticity, and Energetics Determined by Conformational Attuning of Flexible Loops in PD-1. Journal of Chemical Information and Modeling 61:1, pages 358-384.
Crossref
Crossref
Menghui Gao, Yuchen He, Haosheng Tang, Xiangyu Chen, Shuang Liu & Yongguang Tao. (2020) cGAS/STING: novel perspectives of the classic pathway. Molecular Biomedicine 1:1.
Crossref
Crossref
Jrhau Lung, Ming-Szu Hung, Yu-Ching Lin, Chien-Hui Hung, Chih-Cheng Chen, Kuan-Der Lee & Ying Tsai. (2020) Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products. Molecules 25:22, pages 5293.
Crossref
Crossref
Abdulla Al Mamun, Zheng Mei, Ling Qiu & Xue-hai Ju. (2020) Theoretical investigation on QSAR of (2-Methyl-3-biphenylyl) methanol analogs as PD-L1 inhibitor. Chinese Journal of Chemical Physics 33:4, pages 459-467.
Crossref
Crossref
Qingke Li, Qu Chen, Paul C. Klauser, Mengyuan Li, Feng Zheng, Nanxi Wang, Xiaoying Li, Qianbing Zhang, Xuemei Fu, Qian Wang, Yang Xu & Lei Wang. (2020) Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics. Cell 182:1, pages 85-97.e16.
Crossref
Crossref
Zhengping Hu, Pengfei Yu, Guangying Du, Wenyan Wang, Haibo Zhu, Ning Li, Huijuan Zhao, Zhaoju Dong, Liang Ye & Jingwei Tian. (2020) PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. PLOS ONE 15:3, pages e0228339.
Crossref
Crossref
Pengli Zhang, Chengping Li, Xiaoyue Ji, Mingjie Gao, Sifan Lyu, Xiaojun Dai & Jiangfeng Du. (2019) In silico screening and surface plasma resonance‐based verification of programmed death 1‐targeted peptides. Chemical Biology & Drug Design 95:3, pages 332-342.
Crossref
Crossref
Ben Niu, Todd C. Appleby, Ruth Wang, Mariya Morar, Johannes Voight, Armando G. Villaseñor, Sheila Clancy, Sarah Wise, Jean-Philippe Belzile, Giuseppe Papalia, Melanie Wong, Katherine M. Brendza, Latesh Lad & Michael L. Gross. (2019) Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide. Biochemistry 59:4, pages 541-551.
Crossref
Crossref
William James Kelly, Amber Jin Giles & Mark Gilbert. (2020) T lymphocyte-targeted immune checkpoint modulation in glioma. Journal for ImmunoTherapy of Cancer 8:1, pages e000379.
Crossref
Crossref
Marta Spodzieja, Katarzyna Kuncewicz, Adam Sieradzan, Agnieszka Karczyńska, Justyna Iwaszkiewicz, Valérie Cesson, Katarzyna Węgrzyn, Igor Zhukov, Martyna Maszota-Zieleniak, Olivier Michielin, Daniel E. Speiser, Vincent Zoete, Laurent Derré & Sylwia Rodziewicz-Motowidło. (2020) Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. International Journal of Molecular Sciences 21:2, pages 636.
Crossref
Crossref
Xin Lin, Xiang Lu, Guoshun Luo & Hua Xiang. (2020) Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry 186, pages 111876.
Crossref
Crossref
Yongxin Han, Li Zhu, Wei Wu, Hui Zhang, Wei Hu, Liguang Dai & Yanqing Yang. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
547
618
.
Tadashi ASHIZAWA, Akira IIZUKA, Emiko TANAKA, Ryota KONDOU, Haruo MIYATA, Chie MAEDA, Takashi SUGINO, Ken YAMAGUCHI, Takayuki ANDO, Yoshinobu ISHIKAWA, Mamoru ITO & Yasuto AKIYAMA. (2019) Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research 40:6, pages 243-250.
Crossref
Crossref
Rui Zhang, Zhiyan Zhu, Hongying Lv, Futian Li, Shuqing Sun, Juan Li & Chun‐Sing Lee. (2019) Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer. Small 15:49, pages 1903881.
Crossref
Crossref
Danfeng Shi, Xiaoli An, Qifeng Bai, Zhitong Bing, Shuangyan Zhou, Huanxiang Liu & Xiaojun Yao. (2019) Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. Frontiers in Chemistry 7.
Crossref
Crossref
Anna Ju, Sung Won Lee, Young Eun Lee, Ki-Cheol Han, Jin-Chul Kim, Sang Chul Shin, Hyun Jung Park, Eunice EunKyeong Kim, Seokmann Hong & Mihue Jang. (2019) A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials 217, pages 119298.
Crossref
Crossref
Mu-Yang Huang, Xiao-Ming Jiang, Yu-Lian Xu, Luo-Wei Yuan, Yu-Chi Chen, Guozhen Cui, Run-Yue Huang, Bo Liu, Yitao Wang, Xiuping Chen & Jin-Jian Lu. (2019) Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food and Chemical Toxicology 131, pages 110537.
Crossref
Crossref
Aravindhan Ganesan, Marawan Ahmed, Isobel Okoye, Elena Arutyunova, Dinesh Babu, William L. Turnbull, Joydeb Kumar Kundu, Justin Shields, Katharine Cheryl Agopsowicz, Lai Xu, Yasser Tabana, Nutan Srivastava, Guangzhi Zhang, Tae Chul Moon, Alexandr Belovodskiy, Mostofa Hena, Appan Srinivas Kandadai, Seyedeh Nargess Hosseini, Mary Hitt, John Walker, Michael Smylie, Frederick G. West, Arno G. Siraki, M. Joanne Lemieux, Shokrollah Elahi, James A. Nieman, D. Lorne Tyrrell, Michael Houghton & Khaled Barakat. (2019) Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Scientific Reports 9:1.
Crossref
Crossref
Derek J. Blevins, Ronan Hanley, Trevor Bolduc, David A. Powell, Michael Gignac, Kayleigh Walker, Mark D. Carr, Fraser Hof & Jeremy E. Wulff. (2019)
In Vitro
Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action
. ACS Medicinal Chemistry Letters 10:8, pages 1187-1192.
Crossref
Crossref
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A. Holak & Longqin Hu. (2019)
Design, Synthesis, Evaluation, and Structural Studies of
C
2
-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
. Journal of Medicinal Chemistry 62:15, pages 7250-7263.
Crossref
Crossref
Spandana R. Kopalli, Tae-Bong Kang, Kwang-Ho Lee & Sushruta Koppula. (2019) Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery 14:2, pages 100-112.
Crossref
Crossref
Bogdan Musielak, Justyna Kocik, Lukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Miroslawa Czub, Malgorzata Stec, Maciej Siedlar, Tad A. Holak & Jacek Plewka. (2019) CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules 24:15, pages 2804.
Crossref
Crossref
Katarzyna Guzik, Marcin Tomala, Damian Muszak, Magdalena Konieczny, Aleksandra Hec, Urszula Błaszkiewicz, Marcin Pustuła, Roberto Butera, Alexander Dömling & Tad A. Holak. (2019) Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Molecules 24:11, pages 2071.
Crossref
Crossref
Dading Huang, Wei Wen, Xiao Liu, Yang Li & John Z. H. Zhang. (2019) Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction. RSC Advances 9:26, pages 14944-14956.
Crossref
Crossref
Hu Kuan, Hanyu Masayuki, Lin Xie, Yiding Zhang, Nagatsu Kotaro, Suzuki Hisashi & Ming-Rong Zhang. (2019) Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation. Chemical Communications 55:29, pages 4162-4165.
Crossref
Crossref
Manni Wang, Yu Liu, Yuan Cheng, Yuquan Wei & Xiawei Wei. (2019) Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:2, pages 199-224.
Crossref
Crossref
Peifu Jiao, Qiaohong Geng, Peng Jin, Gaoxing Su, Houyun Teng, Jinlong Dong & Bing Yan. (2019) Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Current Pharmaceutical Design 24:41, pages 4911-4920.
Crossref
Crossref
Alexander A. Vinogradov, Yizhen Yin & Hiroaki Suga. (2019) Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. Journal of the American Chemical Society 141:10, pages 4167-4181.
Crossref
Crossref
Evan Perry, Jonathan J. Mills, Bin Zhao, Feng Wang, Qi Sun, Plamen P. Christov, James C. Tarr, Tyson A. Rietz, Edward T. Olejniczak, Taekyu Lee & Stephen Fesik. (2019) Fragment-based screening of programmed death ligand 1 (PD-L1). Bioorganic & Medicinal Chemistry Letters 29:6, pages 786-790.
Crossref
Crossref
Tianyu Wang, Xiaoxing Wu, Changying Guo, Kuojun Zhang, Jinyi Xu, Zheng Li & Sheng Jiang. (2018) Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. Journal of Medicinal Chemistry 62:4, pages 1715-1730.
Crossref
Crossref
Tingkai Chen, Qi Li, Zongliang Liu, Yao Chen, Feng Feng & Haopeng Sun. (2019) Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. European Journal of Medicinal Chemistry 161, pages 378-398.
Crossref
Crossref
Markella Konstantinidou, Tryfon Zarganes-Tzitzikas, Katarzyna Magiera-Mularz, Tad A. Holak & Alexander Dömling. (2018) Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?. Angewandte Chemie International Edition 57:18, pages 4840-4848.
Crossref
Crossref
Markella Konstantinidou, Tryfon Zarganes-Tzitzikas, Katarzyna Magiera-Mularz, Tad A. Holak & Alexander Dömling. (2018) Der Immuncheckpoint PD-1/PD-L1: Gibt es Therapieoptionen jenseits der Antikörper?. Angewandte Chemie 130:18, pages 4932-4940.
Crossref
Crossref
Sachin P. Patil, Madison A. Fink, Erika S. Enley, James E. Fisher, Marie C. Herb, Anthony Klingos, James T. Proulx & Megan T. Fedorky. (2018) Identification of Small‐Molecule Inhibitors of PD‐1/PD‐L1 Protein‐Protein Interaction. ChemistrySelect 3:7, pages 2185-2189.
Crossref
Crossref
Liyan Yue, Wei Wan, Pan Xu, Linjuan Li, Chen Wang, Yuanyuan Zhang, Heng Xu, Rukang Zhang, Junchi Hu, Wenchao Lu, Hao Jiang & Cheng Luo. 2018. Targeting Protein-Protein Interactions by Small Molecules. Targeting Protein-Protein Interactions by Small Molecules
179
211
.
Danfeng Shi, Shuangyan Zhou, Xuewei Liu, Chenxi Zhao, Huanxiang Liu & Xiaojun Yao. (2017) Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective. Biochimica et Biophysica Acta (BBA) - General Subjects.
Crossref
Crossref
Katarzyna Magiera-Mularz, Lukasz Skalniak, Krzysztof M. Zak, Bogdan Musielak, Ewa Rudzinska-Szostak, Łukasz Berlicki, Justyna Kocik, Przemyslaw Grudnik, Dominik Sala, Tryfon Zarganes-Tzitzikas, Shabnam Shaabani, Alexander Dömling, Grzegorz Dubin & Tad A. Holak. (2017) Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Angewandte Chemie International Edition 56:44, pages 13732-13735.
Crossref
Crossref
Katarzyna Magiera‐Mularz, Lukasz Skalniak, Krzysztof M. Zak, Bogdan Musielak, Ewa Rudzinska‐Szostak, Łukasz Berlicki, Justyna Kocik, Przemyslaw Grudnik, Dominik Sala, Tryfon Zarganes‐Tzitzikas, Shabnam Shaabani, Alexander Dömling, Grzegorz Dubin & Tad A. Holak. (2017) Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint. Angewandte Chemie 129:44, pages 13920-13923.
Crossref
Crossref
Isobel S. Okoye, Michael Houghton, Lorne Tyrrell, Khaled Barakat & Shokrollah Elahi. (2017) Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. Frontiers in Immunology 8.
Crossref
Crossref
Lukasz Skalniak, Krzysztof M. Zak, Katarzyna Guzik, Katarzyna Magiera, Bogdan Musielak, Magdalena Pachota, Bozena Szelazek, Justyna Kocik, Przemyslaw Grudnik, Marcin Tomala, Sylwia Krzanik, Krzysztof Pyrc, Alexander Dömling, Grzegorz Dubin & Tad A. Holak. (2017) Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget 8:42, pages 72167-72181.
Crossref
Crossref
Krzysztof M. Zak, Przemyslaw Grudnik, Katarzyna Magiera, Alexander Dömling, Grzegorz Dubin & Tad A. Holak. (2017) Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure 25:8, pages 1163-1174.
Crossref
Crossref
Katarzyna Guzik, Krzysztof M. Zak, Przemyslaw Grudnik, Katarzyna Magiera, Bogdan Musielak, Ricarda Törner, Lukasz Skalniak, Alexander Dömling, Grzegorz Dubin & Tad A. Holak. (2017) Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Journal of Medicinal Chemistry 60:13, pages 5857-5867.
Crossref
Crossref
Marta Spodzieja, S?awomir Lach, Justyna Iwaszkiewicz, Val?rie Cesson, Katarzyna Kalejta, Daniel Olive, Olivier Michielin, Daniel E. Speiser, Vincent Zoete, Laurent Derr? & Sylwia Rodziewicz-Motowid?o. (2017) Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLOS ONE 12:6, pages e0179201.
Crossref
Crossref
Nicolas A Pabon & Carlos J Camacho. (2017) Probing protein flexibility reveals a mechanism for selective promiscuity. eLife 6.
Crossref
Crossref